Corticoid therapy is believed to accelerate the recovery of patients with TTP by inhibiting the production of ADAMTS13 inhibitors, and decreasing cytokine production and autoantibody-mediated clearance of ADAMTS13 [32]. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.